drug

Betahistine

MeSH D001621
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Nathan Kline Institute for Psychiatric Research
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
NCT00709202Phase 2Completed
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
NCT00428168Phase 2Terminated

KOLs & investigators

2
Robert C Smith, M.D., Ph.DKOL score 5
Yaffa Beck

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Nathan Kline Institute for Psychiatric Research
company
trial
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
PHASE2
trial
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
PHASE2
trial
indication
Schizophrenia
indication
Autism Spectrum Disorder
indication
Autism Spectrum Disorder
indication
Weight Gain
indication
KOL
Robert C Smith, M.D., Ph.D
KOL score 5
person
Yaffa Beck
KOL score —
person